Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Goel

Showing results (151-160 of 182) with videos related to

Pageof 19
Sort By:
Investigational New Drugs|June 29, 2022
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumorsTodd Bauer, Byong Chul Cho, Rebecca Heist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid TumorsBonnie S Glisson, Rom S Leidner, Robert L Ferris, et al.
Chemico-Biological Interactions|October 10, 2013
Calreticulin transacetylase mediated upregulation of thioredoxin by 7,8-diacetoxy-4-methylcoumarin enhances the antioxidant potential and the expression of vascular endothelial growth factor in peripheral blood mononuclear cellsRini Joshi, Ajit Kumar, Sushma Manral, et al.
Future Oncology (London, England)|November 8, 2024
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib studyLyudmila Bazhenova, Dong-Wan Kim, Byoung Chul Cho, et al.
Journal for Immunotherapy of Cancer|October 19, 2021
Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trialJoël Guigay, Keun-Wook Lee, Manish R Patel, et al.
BMC Cancer|March 13, 2025
Identifying distinct prognostic and predictive contributions of tumor epithelium versus tumor microenvironment in colorectal cancerMingli Yang, Michael V Nebozhyn, Michael J Schell, et al.
The Lancet. Oncology|June 11, 2022
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)Neeraj Agarwal, Bradley McGregor, Benjamin L Maughan, et al.
Journal for Immunotherapy of Cancer|August 24, 2019
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignanciesAung Naing, Jeffrey Infante, Sanjay Goel, et al.
NPJ Precision Oncology|February 26, 2026
Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancerIbrahim Halil Sahin, Joanne Xiu, Yasmine Baca, et al.
Cancer Research|January 14, 2010
Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene inductionAndrew J Wilson, Anderly C Chueh, Lars Tögel, et al.
Pageof 19

Showing results (151-160 of 182) with videos related to

Sort By:
Pageof 19
Investigational New Drugs|June 29, 2022
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumorsTodd Bauer, Byong Chul Cho, Rebecca Heist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid TumorsBonnie S Glisson, Rom S Leidner, Robert L Ferris, et al.
Chemico-Biological Interactions|October 10, 2013
Calreticulin transacetylase mediated upregulation of thioredoxin by 7,8-diacetoxy-4-methylcoumarin enhances the antioxidant potential and the expression of vascular endothelial growth factor in peripheral blood mononuclear cellsRini Joshi, Ajit Kumar, Sushma Manral, et al.
Future Oncology (London, England)|November 8, 2024
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib studyLyudmila Bazhenova, Dong-Wan Kim, Byoung Chul Cho, et al.
Journal for Immunotherapy of Cancer|October 19, 2021
Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trialJoël Guigay, Keun-Wook Lee, Manish R Patel, et al.
BMC Cancer|March 13, 2025
Identifying distinct prognostic and predictive contributions of tumor epithelium versus tumor microenvironment in colorectal cancerMingli Yang, Michael V Nebozhyn, Michael J Schell, et al.
The Lancet. Oncology|June 11, 2022
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)Neeraj Agarwal, Bradley McGregor, Benjamin L Maughan, et al.
Journal for Immunotherapy of Cancer|August 24, 2019
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignanciesAung Naing, Jeffrey Infante, Sanjay Goel, et al.
NPJ Precision Oncology|February 26, 2026
Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancerIbrahim Halil Sahin, Joanne Xiu, Yasmine Baca, et al.
Cancer Research|January 14, 2010
Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene inductionAndrew J Wilson, Anderly C Chueh, Lars Tögel, et al.
Pageof 19